Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial

Anthony K. Guzman, David O. Schairer, Jessica L. Garelik, Steven R. Cohen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Topical cantharidin is a commonly used treatment for molluscum contagiosum (MC). However, studies validating its safety and efficacy are limited. We conducted a 6-week, randomized, double-blind, placebo-controlled trial with subsequent open-label extension to assess the safety and effectiveness of cantharidin in treating pediatric MC. Ninety-four participants with MC were randomized to receive cantharidin or placebo, with or without occlusion. The primary outcome was complete lesion clearance. Secondary outcomes included post-treatment lesion count, adverse events, and side effects. No significant differences between the study arms, including baseline lesion count, were observed. The overall mean (SD) baseline lesion count was 22.2 (12.9). The number of participants achieving total clearance is as follows: 7/23 (30.4%) in the cantharidin only arm, 10/24 (41.7%) in the cantharidin with occlusion arm, 2/25 (8.0%) in the placebo with occlusion arm, and 3/22 (13.6%) in the placebo only arm. Post hoc analysis demonstrated that 17/47 (36.2%) participants in the combined cantharidin arms achieved clearance compared to 5/47 (10.6%) in the placebo arms (P = 0.0065). The mean (SD) lesion count change from baseline was −5.1 (12.2) in the placebo only arm; the mean change (SD) was −17.4 (12.8) in the cantharidin only arm (P = 0.0033) and −15.9 (11.6) in the cantharidin with occlusion arm (P = 0.0101). No serious adverse events or side effects were observed. Topical cantharidin was well-tolerated and associated with the resolution of MC.

Original languageEnglish (US)
Pages (from-to)1001-1006
Number of pages6
JournalInternational Journal of Dermatology
Volume57
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Cantharidin
Molluscum Contagiosum
Placebos
Pediatrics
Safety
Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum : a prospective, randomized, double-blind, placebo-controlled pilot trial. / Guzman, Anthony K.; Schairer, David O.; Garelik, Jessica L.; Cohen, Steven R.

In: International Journal of Dermatology, Vol. 57, No. 8, 01.08.2018, p. 1001-1006.

Research output: Contribution to journalArticle

@article{e491703ae3c14f74a63d95fa8544b15f,
title = "Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial",
abstract = "Topical cantharidin is a commonly used treatment for molluscum contagiosum (MC). However, studies validating its safety and efficacy are limited. We conducted a 6-week, randomized, double-blind, placebo-controlled trial with subsequent open-label extension to assess the safety and effectiveness of cantharidin in treating pediatric MC. Ninety-four participants with MC were randomized to receive cantharidin or placebo, with or without occlusion. The primary outcome was complete lesion clearance. Secondary outcomes included post-treatment lesion count, adverse events, and side effects. No significant differences between the study arms, including baseline lesion count, were observed. The overall mean (SD) baseline lesion count was 22.2 (12.9). The number of participants achieving total clearance is as follows: 7/23 (30.4{\%}) in the cantharidin only arm, 10/24 (41.7{\%}) in the cantharidin with occlusion arm, 2/25 (8.0{\%}) in the placebo with occlusion arm, and 3/22 (13.6{\%}) in the placebo only arm. Post hoc analysis demonstrated that 17/47 (36.2{\%}) participants in the combined cantharidin arms achieved clearance compared to 5/47 (10.6{\%}) in the placebo arms (P = 0.0065). The mean (SD) lesion count change from baseline was −5.1 (12.2) in the placebo only arm; the mean change (SD) was −17.4 (12.8) in the cantharidin only arm (P = 0.0033) and −15.9 (11.6) in the cantharidin with occlusion arm (P = 0.0101). No serious adverse events or side effects were observed. Topical cantharidin was well-tolerated and associated with the resolution of MC.",
author = "Guzman, {Anthony K.} and Schairer, {David O.} and Garelik, {Jessica L.} and Cohen, {Steven R.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1111/ijd.14079",
language = "English (US)",
volume = "57",
pages = "1001--1006",
journal = "International Journal of Dermatology",
issn = "0011-9059",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum

T2 - a prospective, randomized, double-blind, placebo-controlled pilot trial

AU - Guzman, Anthony K.

AU - Schairer, David O.

AU - Garelik, Jessica L.

AU - Cohen, Steven R.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Topical cantharidin is a commonly used treatment for molluscum contagiosum (MC). However, studies validating its safety and efficacy are limited. We conducted a 6-week, randomized, double-blind, placebo-controlled trial with subsequent open-label extension to assess the safety and effectiveness of cantharidin in treating pediatric MC. Ninety-four participants with MC were randomized to receive cantharidin or placebo, with or without occlusion. The primary outcome was complete lesion clearance. Secondary outcomes included post-treatment lesion count, adverse events, and side effects. No significant differences between the study arms, including baseline lesion count, were observed. The overall mean (SD) baseline lesion count was 22.2 (12.9). The number of participants achieving total clearance is as follows: 7/23 (30.4%) in the cantharidin only arm, 10/24 (41.7%) in the cantharidin with occlusion arm, 2/25 (8.0%) in the placebo with occlusion arm, and 3/22 (13.6%) in the placebo only arm. Post hoc analysis demonstrated that 17/47 (36.2%) participants in the combined cantharidin arms achieved clearance compared to 5/47 (10.6%) in the placebo arms (P = 0.0065). The mean (SD) lesion count change from baseline was −5.1 (12.2) in the placebo only arm; the mean change (SD) was −17.4 (12.8) in the cantharidin only arm (P = 0.0033) and −15.9 (11.6) in the cantharidin with occlusion arm (P = 0.0101). No serious adverse events or side effects were observed. Topical cantharidin was well-tolerated and associated with the resolution of MC.

AB - Topical cantharidin is a commonly used treatment for molluscum contagiosum (MC). However, studies validating its safety and efficacy are limited. We conducted a 6-week, randomized, double-blind, placebo-controlled trial with subsequent open-label extension to assess the safety and effectiveness of cantharidin in treating pediatric MC. Ninety-four participants with MC were randomized to receive cantharidin or placebo, with or without occlusion. The primary outcome was complete lesion clearance. Secondary outcomes included post-treatment lesion count, adverse events, and side effects. No significant differences between the study arms, including baseline lesion count, were observed. The overall mean (SD) baseline lesion count was 22.2 (12.9). The number of participants achieving total clearance is as follows: 7/23 (30.4%) in the cantharidin only arm, 10/24 (41.7%) in the cantharidin with occlusion arm, 2/25 (8.0%) in the placebo with occlusion arm, and 3/22 (13.6%) in the placebo only arm. Post hoc analysis demonstrated that 17/47 (36.2%) participants in the combined cantharidin arms achieved clearance compared to 5/47 (10.6%) in the placebo arms (P = 0.0065). The mean (SD) lesion count change from baseline was −5.1 (12.2) in the placebo only arm; the mean change (SD) was −17.4 (12.8) in the cantharidin only arm (P = 0.0033) and −15.9 (11.6) in the cantharidin with occlusion arm (P = 0.0101). No serious adverse events or side effects were observed. Topical cantharidin was well-tolerated and associated with the resolution of MC.

UR - http://www.scopus.com/inward/record.url?scp=85049618679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049618679&partnerID=8YFLogxK

U2 - 10.1111/ijd.14079

DO - 10.1111/ijd.14079

M3 - Article

C2 - 29904968

AN - SCOPUS:85049618679

VL - 57

SP - 1001

EP - 1006

JO - International Journal of Dermatology

JF - International Journal of Dermatology

SN - 0011-9059

IS - 8

ER -